中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
26期
21-25
,共5页
血浆%胆红素吸附柱%血液灌流器%高胆红素血症
血漿%膽紅素吸附柱%血液灌流器%高膽紅素血癥
혈장%담홍소흡부주%혈액관류기%고담홍소혈증
Plasma%Bilirubin adsorption column%Disposable hemoperfutor%Hyperbilirubinemia
目的：考察胆红素吸附柱联合血液灌流器的吸附系统治疗高胆红素血症的临床效果、护理方式与安全性。方法本文回顾性分析昆明医科大学附属延安医院在2012年9月~2013年12月收治的30例高胆红素血症患者，所有患者在药物综合治疗的基础上接受了这种组合式的治疗方法，患者的血液经过血浆分离器分离出血浆后经血液灌流器(MG-350)吸附后再通过胆红素吸附柱回输至体内。观察和检测患者治疗前后的症状、体征、肝功能、凝血酶原活性、血常规、电解质、炎性因子及治疗中发生的并发症。结果30例患者接受该吸附系统治疗后其体内的总胆红素、直接胆红素、间接胆红素、总胆汁酸的下降幅度为(189.93±95.14)、(106.57±60.71)、(87.81±58.39)、(64.84±26.30)μmol/L。治疗前后比较差异有统计学意义(P<0.05)。结论观察胆红素吸附柱联合血液灌流器的吸附系统是一种新型有效的人工肝支持治疗，可显著降低患者的胆红素水平，改善生化检查指标及部分临床症状，且患者耐受性好。因此，血浆分离灌流方法是一种值得在临床推广应用的人工肝支持疗法。
目的：攷察膽紅素吸附柱聯閤血液灌流器的吸附繫統治療高膽紅素血癥的臨床效果、護理方式與安全性。方法本文迴顧性分析昆明醫科大學附屬延安醫院在2012年9月~2013年12月收治的30例高膽紅素血癥患者，所有患者在藥物綜閤治療的基礎上接受瞭這種組閤式的治療方法，患者的血液經過血漿分離器分離齣血漿後經血液灌流器(MG-350)吸附後再通過膽紅素吸附柱迴輸至體內。觀察和檢測患者治療前後的癥狀、體徵、肝功能、凝血酶原活性、血常規、電解質、炎性因子及治療中髮生的併髮癥。結果30例患者接受該吸附繫統治療後其體內的總膽紅素、直接膽紅素、間接膽紅素、總膽汁痠的下降幅度為(189.93±95.14)、(106.57±60.71)、(87.81±58.39)、(64.84±26.30)μmol/L。治療前後比較差異有統計學意義(P<0.05)。結論觀察膽紅素吸附柱聯閤血液灌流器的吸附繫統是一種新型有效的人工肝支持治療，可顯著降低患者的膽紅素水平，改善生化檢查指標及部分臨床癥狀，且患者耐受性好。因此，血漿分離灌流方法是一種值得在臨床推廣應用的人工肝支持療法。
목적：고찰담홍소흡부주연합혈액관류기적흡부계통치료고담홍소혈증적림상효과、호리방식여안전성。방법본문회고성분석곤명의과대학부속연안의원재2012년9월~2013년12월수치적30례고담홍소혈증환자，소유환자재약물종합치료적기출상접수료저충조합식적치료방법，환자적혈액경과혈장분리기분리출혈장후경혈액관류기(MG-350)흡부후재통과담홍소흡부주회수지체내。관찰화검측환자치료전후적증상、체정、간공능、응혈매원활성、혈상규、전해질、염성인자급치료중발생적병발증。결과30례환자접수해흡부계통치료후기체내적총담홍소、직접담홍소、간접담홍소、총담즙산적하강폭도위(189.93±95.14)、(106.57±60.71)、(87.81±58.39)、(64.84±26.30)μmol/L。치료전후비교차이유통계학의의(P<0.05)。결론관찰담홍소흡부주연합혈액관류기적흡부계통시일충신형유효적인공간지지치료，가현저강저환자적담홍소수평，개선생화검사지표급부분림상증상，차환자내수성호。인차，혈장분리관류방법시일충치득재림상추엄응용적인공간지지요법。
Objective To investigate the therapeutic effect, the nursing methods and the security of the adsorption sys-tem of bilirubin adsorption column combined with disposable hemoperfutor which applied to hyperbilirubinemia. Meth-ods In this paper, a retrospective analysis of a total of 30 patients with hyperbilirubinemia in Yan'an Hospital Affiliated to Kunming Medical University from September 2012 to December 2013 were enrolled. They were treated with the ad-sorption system on the basis of medicine comprehensive treatment, the patients' blood was separated by a plasma sepa-rator plasma then passed a disposable hemoperfutor (MG-350) and bilirubin adsorption column, and then the plasma reflowed back to the body in the end. Their main symptoms, signs, liver function, prothrombin activity, blood count, electrolytes and complications therapy in treatment were observed. Results After treated with the adsorption system, all patients' TBiL, DBiL, IBiL, TBA were significantly lower than before treatment, the reduction was (189.93±95.14), (106.57±60.71), (87.81±58.39), (64.84±26.30) μmol/L, respectively. The differences between before and after treatment were statistically significant (P < 0.05). Conclusion The adsorption system of bilirubin adsorption column combined with disposable hemoperfutor is a new type of effective artificial liver support therapy, which can significantly reduce bilirubin in the body and improve biochemical parameters, and has good patients' tolerance. So the plasma separation perfusion method is worthy of clinical application of artificial liver support therapy.
